Takeda released topline results for their Phase 3 study of zasocitinib today. It's an oral treatment for plaque psoriasis. The drug met all primary and secondary endpoints. Over half the patients achieved clear or almost clear skin by week 16, and about 30% were completely clear. It outperformed the placebo and the active comparator. They plan to submit an NDA to the FDA starting in fiscal year 2026. This doesn't change their financial outlook for the current year, but it validates the pipeline.